These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24382005)

  • 1. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
    Silveira MG; Lindor KD
    Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in pharmacotherapy for primary biliary cirrhosis.
    Mousa HS; Lleo A; Invernizzi P; Bowlus CL; Gershwin ME
    Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
    Akepati PR; Gochanour EM
    Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor agonists for primary biliary cirrhosis.
    Lindor KD
    Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary biliary cirrhosis and bile acids.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obeticholic acid for the treatment of primary biliary cirrhosis.
    Trivedi PJ; Hirschfield GM; Gershwin ME
    Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Parés A
    Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New name and new treatments for primary biliary cholangitits].
    Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
    Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary biliary cholangitis: Old and novel therapy.
    Floreani A; Mangini C
    Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern treatment of primary biliary cholangitis].
    Strassburg CP
    Internist (Berl); 2018 Jan; 59(1):105-112. PubMed ID: 29110023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and potential treatments for primary biliary cholangitis.
    Shah RA; Kowdley KV
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.